We dive into the recognition and management of blast crisis.
Sadakat Chowdhury, MD
https://media.blubrry.com/coreem/content.blubrry.com/coreem/Blast_Crisis.mp3
Download
Leave a Comment
Tags: Hematology, Oncology
Show Notes
Topic Overview
Blast crisis is an oncologic emergency, most commonly seen in chronic myeloid leukemia (CML).Defined by:>20% blasts in peripheral blood or bone marrow.May include extramedullary blast proliferation.Without treatment, median survival is only 3–6 months.Pathophysiology & Associated Conditions
Usually occurs in CML, but also in:Myeloproliferative neoplasms (MPNs)Myelodysplastic syndromes (MDS)Transition from chronic to blast phase often reflects disease progression or treatment resistance.Risk Factors
10% of CML patients progress to blast crisis.Risk increased in:Patients refractory to tyrosine kinase inhibitors (e.g., imatinib).Those with Philadelphia chromosome abnormalities.WBC >100,000, which increases risk for leukostasis.Clinical Presentation
Symptoms often stem from pancytopenia and leukostasis:Anemia: fatigue, malaise.Functional neutropenia: high WBC count, but increased infection/sepsis risk.Thrombocytopenia: bleeding, bruising.Leukostasis/hyperviscosity effects by system:Neurologic: confusion, visual changes, stroke-like symptoms.Cardiopulmonary: ARDS, myocardial injury.Others: priapism, limb ischemia, bowel infarction.Rapid deterioration is common — early recognition is critical.Diagnostic Workup
CBC with differential: assess blast % and cytopenias.Peripheral smear and manual diff: confirm immature blasts.CMP: screen for tumor lysis syndrome:Elevated potassium, phosphate, uric acid.Low calcium.LDH & uric acid: markers of high cell turnover.Coagulation studies (PT, PTT): assess for DIC.Definitive tests (done inpatient): bone marrow biopsy, flow cytometry.Emergency Department Management
Resuscitation & ABCs: oxygen, IV fluids, vitals monitoring.Avoid aggressive transfusions:Risk of hyperviscosity with PRBCs and platelets.Initiate broad-spectrum antibiotics early:High suspicion for sepsis in functionally neutropenic patients.Consider antifungals for prolonged febrile neutropenia.Cytoreduction strategies:Hydroxyurea to lower WBCs quickly.Tyrosine kinase inhibitors (TKIs).High-dose chemotherapy.Early consultation with hematology/oncology is essential.Mutation testing may guide targeted therapy.Prognosis
Without treatment: median survival ~3 months.With treatment:Potential survival >1 year.Best outcomes in patients who enter a second chronic phase and undergo allogeneic stem cell transplant.Ethical & Logistical Considerations
Treatment may involve aggressive interventions with serious side effects.Important to assess:Patient goals of care.Capacity for informed consent.Resource limitations:Not all hospitals have oncology services.Patients may require transfer over long distances.Emphasize early, transparent discussions with patients and families.Top 3 Take-Home Points
Recognize early: Look for cytopenias, leukostasis, and rapid clinical decline.Resuscitate appropriately: Start antibiotics; be cautious with transfusions.Call for help: Early hematology/oncology involvement is essential for definitive care.
Read More